[Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity]

Abstract

Developments in the knowledge of molecular biology of cancer over the past 20 years have been identified. Angiogenesis is playing a key role in the physiopathology of cancer evolution. Several strategies have been developed to target angiogenesis for the treatment of metastatic RCC. These include inhibition of VEGF receptors (inhibition of the tyrosine kinase activity) or binding to the VEGF protein. Several additional kinases inhibitions including PDGF receptors are also targeted. Anti-angiogenic drugs recently marketed or still under clinical development, may interact with the kidneys. Clinical and pathological, and mechanisms of their renal toxicity are presented in this article.